RLMD — Relmada Therapeutics, Inc.

Is RLMD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Relmada Therapeutics, Inc. (RLMD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $4.85. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage company with limited near-term revenues and valuation tied closely to upcoming clinical and financing catalysts. The upside case rests on successful trial readouts or strategic partnerships that de‑risk programs and secure financing on favorable terms. Key near-term drivers are clinical execution, cash runway and any partnering or financing announcements. Major downside scenarios include negative trial outcomes, extended timelines, or dilutive financing. Given the current market tone which is modestly risk-on, short-term trading may be sensitive to sector flows and headline-driven volatility.

Key factors

  • Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biopharma with lead programs that, if successful, could address sizeable unmet needs and drive commercialization value.
  • Upcoming clinical and regulatory catalysts (trial readouts, partner/regulatory interactions) create binary upside potential and can materially re-rate the equity.
  • Relmada's pipeline focus gives it differentiated scientific optionality versus non‑specialty peers; small-cap status provides M&A or partnership optionality if data are compelling.
  • Current market environment is modestly risk-on, which tends to favor growth/biotech exposure and can support short-term upside on positive news.
  • Limited revenue and reliance on external funding highlight the importance of cash runway and financing terms for near-term survival and dilution outcomes.

Risks

  • Clinical execution risk: negative or inconclusive trial results would materially reduce valuation.
  • Financing and dilution risk: small-cap clinical biotechs often need to raise capital; unfavorable terms could significantly dilute existing shareholders.
  • Regulatory and timeline risk: delays in trials or regulatory review processes can extend cash burn and compress upside.
  • Commercialization and competitive risk: even with approval, competition from larger incumbents and generics could limit market penetration.
  • Liquidity and volatility: thin trading and high beta typical of small biotech stocks can amplify price swings and investor losses.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RLMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.